O	0	1	A
B-intervention	2	9	Dietary
O	10	22	Intervention
O	23	25	to
O	26	31	Lower
O	32	37	Serum
O	38	44	Levels
O	45	47	of
O	48	51	IGF
O	51	52	-
O	52	53	I
O	54	56	in
O	57	61	BRCA
O	62	70	Mutation
O	71	79	Carriers
O	79	80	.

O	81	88	Insulin
O	88	89	-
O	89	93	like
O	94	100	growth
O	101	107	factor
O	108	109	I
O	110	111	(
O	111	114	IGF
O	114	115	-
O	115	116	I
O	116	117	)
O	118	121	and
O	122	127	other
O	128	135	markers
O	136	138	of
O	139	146	insulin
O	147	157	resistance
O	158	159	(
O	159	162	IRm
O	162	163	)
O	164	169	might
O	170	179	influence
O	180	183	the
O	184	194	penetrance
O	195	197	of
O	198	202	BRCA
O	203	207	gene
O	208	216	mutation
O	216	217	.

O	218	220	In
O	221	222	a
O	223	236	demonstration
O	237	244	project
O	245	247	on
O	248	252	BRCA
O	253	261	mutation
O	262	270	carriers
O	271	273	we
O	274	280	tested
O	281	284	the
O	285	291	effect
O	292	294	of
O	295	298	the
O	299	300	'
O	300	313	Mediterranean
O	314	318	diet
O	318	319	'
O	319	320	,
O	321	325	with
O	326	334	moderate
O	335	342	protein
O	343	354	restriction
O	354	355	,
O	356	358	on
O	359	364	serum
O	365	371	levels
O	372	374	of
O	375	378	IGF
O	378	379	-
O	379	380	I
O	381	384	and
O	385	388	IRm
O	388	389	.

B-eligibility	390	394	BRCA
I-eligibility	395	403	mutation
I-eligibility	404	412	carriers
I-eligibility	412	413	,
I-eligibility	414	418	with
I-eligibility	419	421	or
I-eligibility	422	429	without
I-eligibility	430	436	breast
I-eligibility	437	443	cancer
O	443	444	,
O	445	449	aged
B-age	450	452	18
I-age	452	453	‚Åª
I-age	453	455	70
I-age	456	461	years
O	462	465	and
B-eligibility	466	473	without
I-eligibility	474	484	metastases
O	485	489	were
O	490	498	eligible
O	498	499	.

O	500	505	After
O	506	509	the
O	510	518	baseline
O	519	531	examinations
O	531	532	,
O	533	538	women
O	539	543	were
O	544	554	randomized
O	555	557	to
O	558	560	an
O	561	567	active
O	568	575	dietary
O	576	588	intervention
O	589	591	or
O	592	594	to
O	595	596	a
B-control	597	604	control
I-control	605	610	group
O	610	611	.

O	612	615	The
O	616	628	intervention
O	629	634	group
O	635	643	attended
O	644	647	six
O	648	652	full
O	653	657	days
O	658	660	of
O	661	665	life
O	665	666	-
O	666	671	style
O	672	684	intervention
O	685	695	activities
O	696	697	(
O	697	704	cookery
O	705	712	classes
O	713	721	followed
O	722	724	by
O	725	730	lunch
O	730	731	,
O	732	740	sessions
O	741	743	of
O	744	751	walking
O	752	755	for
O	756	758	45
O	759	762	min
O	763	766	and
O	767	778	nutritional
O	779	790	conferences
O	790	791	)
O	792	796	over
O	797	800	the
O	801	805	next
O	806	809	six
O	810	816	months
O	816	817	.

B-total-participants	818	821	213
O	822	826	BRCA
O	827	835	mutation
O	836	844	carriers
O	845	854	completed
O	855	858	the
O	859	862	six
O	862	863	-
O	863	868	month
O	869	874	study
O	874	875	.

O	876	881	Women
O	882	884	in
O	885	888	the
O	889	901	intervention
O	902	907	group
O	908	909	(
B-intervention-participants	909	912	110
O	912	913	)
O	914	920	showed
B-outcome	921	926	major
I-outcome	927	934	changes
I-outcome	935	937	in
I-outcome	938	941	all
I-outcome	942	945	the
I-outcome	946	956	parameters
I-outcome	957	962	under
I-outcome	963	968	study
O	968	969	.

O	970	974	They
O	975	988	significantly
B-outcome	989	993	lost
I-outcome	994	1000	weight
O	1001	1002	(
O	1002	1003	p
O	1004	1005	<
O	1006	1007	0
O	1007	1008	.
O	1008	1011	001
O	1011	1012	)
O	1012	1013	,
B-outcome	1014	1017	fat
I-outcome	1018	1022	mass
O	1023	1024	(
O	1024	1025	p
O	1026	1027	=
O	1028	1029	0
O	1029	1030	.
O	1030	1033	002
O	1033	1034	)
O	1034	1035	,
O	1036	1040	with
O	1041	1048	reduced
B-outcome	1049	1052	hip
I-outcome	1053	1066	circumference
O	1067	1068	(
O	1068	1069	p
O	1070	1071	=
O	1072	1073	0
O	1073	1074	.
O	1074	1076	01
O	1076	1077	)
O	1077	1078	,
B-outcome	1079	1092	triglycerides
O	1093	1094	(
O	1094	1095	p
O	1096	1097	=
O	1098	1099	0
O	1099	1100	.
O	1100	1102	02
O	1102	1103	)
O	1104	1107	and
B-outcome	1108	1111	IGF
I-outcome	1111	1112	-
I-outcome	1112	1113	I
O	1114	1115	(
O	1115	1116	p
O	1117	1118	=
O	1119	1120	0
O	1120	1121	.
O	1121	1123	02
O	1123	1124	)
O	1125	1133	compared
O	1134	1138	with
O	1139	1147	controls
O	1147	1148	.

O	1149	1153	They
O	1154	1158	also
O	1159	1162	had
O	1163	1164	a
O	1165	1178	significantly
O	1179	1185	higher
B-outcome	1186	1192	levels
I-outcome	1193	1195	of
I-outcome	1196	1203	insulin
I-outcome	1203	1204	-
I-outcome	1204	1208	like
I-outcome	1209	1215	growth
I-outcome	1216	1222	factor
I-outcome	1222	1223	-
I-outcome	1223	1230	binding
I-outcome	1231	1238	protein
I-outcome	1239	1240	3
I-outcome	1241	1242	(
I-outcome	1242	1246	IGFI
I-outcome	1246	1247	-
I-outcome	1247	1250	BP3
I-outcome	1250	1251	)
O	1252	1253	(
O	1253	1254	p
O	1255	1256	=
O	1257	1258	0
O	1258	1259	.
O	1259	1261	03
O	1261	1262	)
O	1263	1266	and
O	1267	1268	a
O	1269	1274	lower
B-outcome	1275	1278	IGF
I-outcome	1278	1279	-
I-outcome	1279	1280	I
I-outcome	1280	1281	/
I-outcome	1281	1285	IGFI
I-outcome	1285	1286	-
I-outcome	1286	1289	BP3
I-outcome	1290	1295	ratio
O	1296	1297	(
O	1297	1298	p
O	1299	1300	=
O	1301	1302	0
O	1302	1303	.
O	1303	1305	04
O	1305	1306	)
O	1306	1307	.

O	1308	1311	The
O	1312	1321	reduction
O	1322	1324	of
O	1325	1330	serum
O	1331	1337	levels
O	1338	1340	of
O	1341	1344	IGF
O	1344	1345	-
O	1345	1346	I
O	1347	1350	was
O	1351	1364	significantly
O	1365	1375	associated
O	1376	1380	with
O	1381	1384	the
O	1385	1394	reduction
O	1395	1397	in
O	1398	1401	the
O	1402	1413	consumption
O	1414	1416	of
O	1417	1423	animal
O	1424	1432	products
O	1433	1434	(
O	1434	1435	p
O	1436	1437	=
O	1438	1439	0
O	1439	1440	.
O	1440	1442	04
O	1442	1443	)
O	1443	1444	.

O	1445	1450	Women
O	1451	1453	in
O	1454	1457	the
O	1458	1470	intervention
O	1471	1476	group
O	1477	1483	showed
O	1484	1495	significant
O	1496	1508	improvements
O	1509	1511	in
O	1512	1515	IGF
O	1515	1516	-
O	1516	1517	I
O	1518	1521	and
O	1522	1524	in
O	1525	1530	other
O	1531	1534	IRm
O	1535	1539	that
O	1540	1545	might
O	1546	1555	influence
O	1556	1559	the
O	1560	1570	penetrance
O	1571	1573	of
O	1574	1578	BRCA
O	1579	1588	mutations
O	1588	1589	.
